SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MRE (medco research) -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (122)9/21/1998 9:56:00 AM
From: Invest2Ride  Respond to of 192
 
MRE has a number of adenosine receptor agonists/antagonists in the FDA pipeline. They may have been turned down for approval for one of these. Usually, this means that their clinical trial data is not as comprehensive or compelling as FDA wishes it to be. They will have to decide whether the trend seen in existing data is compelling enough to expend the money for more trials.

Do you remember the product?

I am fairly familiar with the adenosine literature. I am researching whether adenosine receptors play a role in wound healing. I'm developing an in vitro model system that can be used in Phase I-III clinical trials.



To: Scott H. Davis who wrote (122)9/21/1998 6:36:00 PM
From: Sam  Read Replies (1) | Respond to of 192
 
I haven't seen the II issue so can't comment on what it said about MRE. You know that MRE management recently chose to back off a test when they found that an expanded test could provide far greater coverage and save costs and time. Could there be confusion with this decision. At least the call for a strong move was right on! Sam


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News